<< Back to Chromatin Club Home Page

Boston Epigenetic Society Seminar Series

Boston Epigenetic Society (BES)

The Boston Epigenetic Society has been founded to:

  • Promote epigenetics and epitranscriptomics
  • Foster research connections between academics and industry epigenetics scientists
  • Help promote new methods
  • Create a support system for experimental epigenetics research

The Society brings together both academic and industry partners all sharing a passion for epigenetics. Founding members represent the following institutions and companies: Accent Therapeutics, Alkermes, Astellas Pharma, AstraZeneca, Constellation Pharmaceuticals, Ring Therapeutics, Sanofi, Beth Israel Deaconess Medical School, Broad Institute, Harvard Medical School, Harvard University, Massachusetts General Hospital, University of Massachusetts Medical School

For more information about the organization and events, please visit and join the BES LinkedIn Group.

Attendance is free of charge, but registration is required.

Upcoming Event Details

Date: September 21, 2023

Time: 9:00 a.m. (PT) / 12:00 p.m. (ET)

Topic: Biology of NSD2 and Clinical Opportunities for KTX-1001, the First NSD2 Inhibitor to Enter the Clinic

Featured Presenters:

  • Terry Connolly, Ph.D. – CEO, K36 Therapeutics
  • Or Gozani, M.D., Ph.D. – Dr. Morris Herzstein Professor of Biology, Stanford University

Register Now

Previous Event Details

Date: May 18, 2023

Time: 9:00 a.m. (PT) / 12:00 p.m. (ET)

Featured Presenter:

  • John Rinn, Ph.D. – Leslie Orgel Professor of RNA Science at University of Colorado, Boulder
    The Role of lncRNAs in Transcriptional Regulation

    Watch the Presentation